Your session is about to expire
← Back to Search
CIN-107 for High Blood Pressure
Study Summary
This trial will evaluate the long-term safety and effectiveness of CIN-107, a medication for high blood pressure, in patients who have completed an earlier trial.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 trial • 275 Patients • NCT04519658Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Male patients must agree to abstain from sperm donation from Day 1 through 90 days after the final dose of study drug.You are planning to start taking certain medications to stimulate red blood cell production or have a planned blood transfusion within 2 months of joining the study.You are taking or are going to take certain medications that could interfere with the study drug.You have had major heart surgery or procedures during the study period.You are planning to have dialysis or a kidney transplant during the study.You are allergic to CIN-107 or similar medications.You have completed the study.Have had acceptable safety and tolerability during Study CIN-107-124 as determined by the Investigator or Medical Monitor.You have taken your prescribed high blood pressure medication regularly, between 70% and 120% of the time, during a previous study.You have consistently taken your prescribed high blood pressure medication during the previous study.You have been diagnosed with severe chronic heart failure.Women who can have babies and are not surgically unable to have babies must have a negative pregnancy test when they first join the study.Your average blood pressure is very high, with the top number (systolic) being 170 or higher, or the bottom number (diastolic) being 105 or higher.You have had a serious viral infection like hepatitis B, hepatitis C, or HIV during the study.You have a serious heart condition that blocks blood flow from the heart.You have been diagnosed with cancer, except for non-serious skin cancers that can be easily removed.You have other health conditions that could cause high blood pressure, except for obstructive sleep apnea.You had a stroke, heart attack, or were hospitalized for heart failure during Study CIN-107-124.
- Group 1: Experimental 2 mg CIN-107 tablets QD
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What risks come with the utilization of CIN-107?
"Evidence of CIN-107's safety is available, thus earning it a score of 2. However, as this is only on Phase 2 trial there are no studies to support its efficacy yet."
Are there any vacancies available for prospective participants of this examination?
"Unfortunately, according to the clinicaltrials.gov database this study is no longer accepting applications as it was last updated on November 18th 2022. Despite that, there are still 746 other trials actively recruiting participants at present time."
To what extent is participation in this clinical study open to the general public?
"This clinical trial is set to accept 176 subjects, with ages ranging from 18 years old up to 100. As well as this basic requirement, candidates must have completed either Part 1 or 2 of Study CIN-107-124, maintained a adherence rate between 70 and 120 percent when taking their single hypertensive agent and the placebo during that study, abstained from sperm donation for male patients over 90 days after the last dose of medicine for female patients who are potentially childbearing age (and thus not surgically sterile) there has to be a negative serum pregnancy test at enrollment - alongside these individuals having had acceptable safety and tolerability in previous trials"
Does this medical trial allow for people aged fifty and above to participate?
"This clinical trial mandates that all participants are aged between 18 and 100. 54 studies have been conducted with those under the age of majority, while 660 trials were done on seniors (65+)."
Are there numerous locations in North America conducting this research?
"This investigation encompasses 38 different centres, such as CinCor Site 18 in Clearwater, CinCor Site 54 located in Miami and CinCor 24 based out of Columbus. There are also 35 other sites participating."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger